Brief: Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311
04/09/2024 12:31
Sept 4 (Reuters) - Invivyd Inc IVVD.O :
* INVIVYD DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL
OF
VYD2311, A NEXT GENERATION MONOCLONAL ANTIBODY CANDIDATE FOR
COVID-19, BUILDING ON THE SUCCESS OF PEMGARDA™
* INVIVYD INC - PRELIMINARY DATA READOUTS EXPECTED IN Q4
2024
* INVIVYD INC - ANTICIPATES ADDITIONAL CLINICAL READOUTS
FROM
VYD2311 PROGRAM THROUGHOUT 2025
Source text for Eikon: ID:nGNXbSqR5C
Further company coverage: IVVD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview